33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)
    Meeting Abstract

    Shah, N. J.; Beckermann, K.; Vogelzang, N. J.; Mao, S. S.; Ornstein, M. C.; Hammers, H. J.; Gao, X.; McDermott, D. F.; Haas, N. B.; Yan, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Development of Memorial Sloan Kettering (MSK) surgery stress score for older adults with cancer
    Meeting Abstract

    Shahrokni, A.; Tin, A. L.; Downey, R. J.; Bochner, B. H.; Nash, G. M.; Kim, S. J.; Afonso, A.; Korc-Grodzicki, B.; Vickers, A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Cancer doesn't know what day of the week it is: Temporal trends in day of death, 2000-2017
    Meeting Abstract

    Shah, K.; Tao, A.; Chino, J. P.; Chino, F.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic and molecular features associated with response to anti-HER2 therapy in endometrial cancer
    Meeting Abstract

    Shen, S.; Ma, W.; Zhou, Q.; Iasonos, A.; Zhang, Y.; Ross, D. S.; Makker, V.; Chui, M. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Schuster, S. J.; Huw, L. Y.; Bolen, C. R.; Assouline, S. E.; Bartlett, N. L.; Budde, L. E.; Matasar, M. J.; Koeppen, H.; Piccione, E. C.; Wilson, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Serrano, C.; Bauer, S.; GoĢmez-Peregrina, D.; Kang, Y. K.; Jones, R. L.; Rutkowski, P.; Mir, O.; Heinrich, M. C.; Tap, W. D.; Newberry, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers
    Meeting Abstract

    Sepesi, B.; Jones, D. R.; Meyers, B. F.; Chaft, J. E.; Sholl, L. M.; Shyr, Y.; Kelly, K.; Lin, J.; Bunn, P. A.; Minna, J. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy
    Meeting Abstract

    Sallman, D. A.; Foran, J. M.; Watts, J. M.; Stein, E.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Galle, P. R.; Kelley, R. K.; Charoentum, C.; De Toni, E. N.; Ostapenko, Y.; Heo, J.; Cheng, A. L.; Vogel, A.; Marcovitz, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save